Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 90023 

Date: December 3, 2024. 

Time: 11:00 a.m.–12:00 p.m. 

Agenda: The Novel and Exceptional 

Technology and Research Advisory 

Committee (NExTRAC) will receive an 

update from the Working Group on Engaging 

the Public as Partners in Clinical Research 

and discuss the next steps regarding the 

current charge to the committee, delivered in 

August 2023. 

Address: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Suite 

630, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Meeting Access Link: Virtual Meeting Link 

will be available at https://osp.od.nih.gov/ 

policies/novel-and-exceptional-technologyand-research-advisory-committeenextrac#tab4/. 

Contact Person: Jessica Tucker, Ph.D., 

Office of Science Policy, National Institutes 

of Health, 6705 Rockledge Drive, Suite 630, 

Bethesda, MD 20892, 301–496–9838, 

SciencePolicy@od.nih.gov. 

Any interested person may file written 

comments by forwarding the statement to the 

Contact Person listed on this notice at least 

two business days prior to the meeting date. 

The statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. Other 

than name and contact information, please 

do not include any personally identifiable 

information or any information that you do 

not wish to make public. Proprietary, 

classified, confidential, or sensitive 

information should not be included in your 

comments. Please note that any comments 

NIH receives may be posted unredacted to 

the Office of Science Policy website. 

Information is also available on the NIH 

Office of Science Policy website: https://

osp.od.nih.gov/policies/novel-andexceptional-technology-and-researchadvisory-committee-nextrac#tab4, where an 

agenda, link to the webcast meeting, and any 

additional information for the meeting will 

be posted when available. Materials for this 

meeting will be posted prior to the meeting. 

Please check this website for updates. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: November 7, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26426 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Arthritis and 

Musculoskeletal and Skin Diseases 

Advisory Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The open 

session will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (https://

videocast.nih.gov/). 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Arthritis and 

Musculoskeletal and Skin Diseases Advisory 

Council. 

Date: January 28, 2025. 

Open: 9:30 a.m. to 3:00 p.m. 

Agenda: Call to Order; NIAMS Director’s 

Report and Discussion; Open Discussion. 

Address: National Institutes of Health, 31 

Center Street, Bethesda, MD 20892, (Virtual 

Meeting). 

Closed: 3:15 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Address: National Institutes of Health, 31 

Center Street, Bethesda, MD 20892, Virtual 

Meeting. 

Contact Person: Darren D. Sledjeski, Ph.D., 

Director, Division of Extramural Activities 

(DEA), National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 6701 

Democracy Blvd., Bethesda, MD 20892, (301) 

451–7766, darren.sledjeski@nih.gov. 

Any interested person may file 

written comments with the committee 

by forwarding the statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/ 

about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All 

visitor vehicles, including taxicabs, 

hotel, and airport shuttles will be 

inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal 

facility will be asked to show one form 

of identification (for example, a 

government-issued photo ID, driver’s 

license, or passport) and to state the 

purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.niams.nih.gov/about/workinggroups/advisory-council, where an 

agenda and any additional information 

for the meeting will be posted when 

available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: November 8, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–26479 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government Owned Inventions 

Available for Licensing or 

Collaboration: Machine Learning 

Model for the Prioritization of Cancer 

Neoepitopes 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

giving notice of licensing and 

collaboration opportunities for the 

inventions listed below, which are 

owned by an agency of the U.S. 

Government and are available for 

license and collaboration in the U.S. to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to a collaboration 

opportunity should be directed to: Aida 

Cremesti, Senior Technology Transfer 

Manager, NCI, Technology Transfer 

Center, Email: aida.cremesti@nih.gov or 

Phone: 240–276–6641. Inquiries related 


ddrumheller on DSK120RN23PROD with NOTICES1
90024 Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 

to licensing should be directed to 

Andrew Burke, Ph.D., Senior 

Technology Transfer Manager, NCI, 

Technology Transfer Center, Email: 

burkear@mail.nih.gov or Phone: 240– 

276–5484. 

SUPPLEMENTARY INFORMATION: Success in 

immunotherapy is often attributable to 

the reactivity of patient T-cells to 

specific mutated peptide(s) found in the 

patient’s tumor known as neoepitopes. 

In the development of patient-specific 

immunotherapies, there is no consistent 

standard for prioritizing such 

neoepitopes. Current models arrive at a 

ranked list of potential candidates by 

removing epitopes based on predetermined criteria which might lead to 

the elimination of known reactive 

neoepitopes. Identification, 

prioritization and targeting of patient 

neoepitopes are crucial for developing 

effective, personalized treatments. 

Ranking or prioritizing neoepitopes is 

especially important when trying to 

construct a cancer vaccine that will 

elicit a therapeutically beneficial 

immune response. Accordingly, 

scientists at the NCI created a novel 

approach to identify and prioritize 

patient neoantigens. This model uses a 

training dataset of known neoantigens 

from patient screening and determines 

features of importance to epitope 

recognition using both reactive and nonreactive epitopes. The machine learning 

algorithm scores epitopes for their 

likelihood of reactivity and provides a 

stable, reproducible method to prioritize 

epitopes that can be used anywhere. 

This Notice is in accordance with 35 

U.S.C. 209 and 37 CFR part 404. 

NIH Reference Number: E–022–2024– 

0. 

Potential Commercial Applications 

• Oncology. 

• Prioritization of neoantigens for the 

development of effective personalized 

therapies: 

Æ Cancer vaccines. 

Æ TIL and T-cell receptor therapies. 

• Add-on to current color fundus 

imaging modalities. 

Competitive Advantages 

• Model is trained using a dataset of 

verified neoantigens from patient tumor 

data. 

• Model is unbiased because it does 

not use prior assumptions about what 

features a neoepitope should have. 

• Uses two models (MMP and NMER 

model) as a more reproducible approach 

than a single model. 

• Particularly useful for prioritizing 

epitopes for patients with large numbers 

of mutations. 

Publication: A machine learning 

model for ranking candidate HLA class 

I neoantigens based on known 

neoepitopes from multiple human 

tumor types. (PMID: 34927080). 

Product Type: Research Tool. 

Development Stage: Prototype. 

Therapeutic Area(s): Cancer. 

Dated: November 8, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–26464 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board (NCAB) and NCI Board 

of Scientific Advisors (BSA). 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public as indicated below. 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/. 

A portion of the National Cancer 

Advisory Board meeting will be closed 

to the public in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended. 

The intramural programs and projects 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the 

intramural programs and projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Date: December 2, 2024. 

Open: 6:00 p.m. to 9:00 p.m. 

Agenda: National Cancer Advisory Board 

Subcommittee Meetings. 

Place: Gaithersburg Marriott 

Washingtonian Center, Room—TBD, 9751 

Washington Boulevard, Gaithersburg, MD 

20878 (In Person Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Name of Committee: National Cancer 

Advisory Board. 

Date: December 3, 2024. 

Closed: 8:00 a.m. to 8:45 a.m. 

Agenda: Review of intramural program site 

visit outcomes and the discussion of 

confidential personnel issues. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Room 

TE406 & 408, Rockville, MD 20850 (In Person 

and Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892 240–276–6340, grayp@

mail.nih.gov. 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: December 3, 2024. 

Open: 9:00 a.m. to 4:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Director’s report and 

presentations, NCI Board of Scientific 

Advisors Concepts Review. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Room 

TE406 & 408, Rockville, MD 20850 (In Person 

and Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room 7W444, 

Bethesda, MD 20892 240–276–6340 grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NCI-Shady Grove campus. All 

visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: NCAB: http:// 

deainfo.nci.nih.gov/advisory/ncab/ 

ncab.htm,BSA: http://deainfo.nci.nih.gov/ 

advisory/bsa/bsa.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 


ddrumheller on DSK120RN23PROD with NOTICES1